Article
Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jan 2021
Aglago Elom K, Rinaldi Sabina, Freisling Heinz, Jiao Li, Hughes David J, Fedirko Veronika, Schalkwijk Casper G, Weiderpass Elisabete, Dahm Christina C, Overvad Kim, Eriksen Anne Kirstine, Kyrø Cecilie, Boutron-Ruault Marie-Christine, Rothwell Joseph A, Severi Gianluca, Katzke Verena, Kühn Tilman, Schulze Matthias B, Aleksandrova Krasimira, Masala Giovanna, Krogh Vittorio, Panico Salvatore, Tumino Rosario, Naccarati Alessio, Bueno-de-Mesquita Bas, van Gils Carla H, Sandanger Torkjel M, Gram Inger T, Skeie Guri, Quirós J Ramón, Jakszyn Paula, Sánchez Maria-Jose, Amiano Pilar, Huerta José María, Ardanaz Eva, Johansson Ingegerd, Harlid Sophia, Perez-Cornago Aurora, Mayén Ana-Lucia, Cordova Reynalda, Gunter Marc J, Vineis Paolo, Cross Amanda J, Riboli Elio, Jenab Mazda
Abstract excerpt
BACKGROUND: Overexpression of the receptor for advanced glycation end-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation. METHODS: To investigate whether sRAGE and related genetic variants are associated with...
Read the complete abstract on PubMed